Editorial Commentary FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer Faustine X. Luo, Zhaohui Liao Arter, Sai-Hong Ignatius Ou, Misako Nagasaka